Text Size

Trial Using Integuseal as Microbial Sealant for Arterial Bypass Surgery on Lower Extremities (ITT)

This study is not yet open for participant recruitment.
Verified August 2011 by Rijnstate Hospital
Sponsor:
Collaborator:
Kimberly-Clark Corporation
Information provided by:
Rijnstate Hospital
ClinicalTrials.gov Identifier:
NCT00940979
First received: July 16, 2009
Last updated: August 8, 2011
Last verified: August 2011
History of Changes
  Purpose

The purpose of this study is to prove a reduction of postoperative wound infections after direct preoperative use of a microbial sealant in the form of Integuseal for vascular procedures on lower extremities.


Condition Intervention
Arterial Obstructive Diseases
 Procedure: Application of Integuseal sealant

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Prevention
Official Title: Prospective Randomised Trial Using Integuseal as Microbial Sealant for Arterial Bypass Surgery on Lower Extremities

Further study details as provided by Rijnstate Hospital:

Primary Outcome Measures:
  • Postoperative wound infections

Secondary Outcome Measures:
  • Costs of the use of Integuseal
  • Complications during hospital stay

Estimated Enrollment: 450
Arms Assigned Interventions
No Intervention: No use of integuseal
Experimental: Use of Integuseal
Application of a layer of Integuseal (Cyanoacrylate) from a ready to use applicator preoperative before incision Polymerisation immobilise the bacteria that survived the conventional skin preparation This way there will be les contamination of the wound.
 Procedure: Application of Integuseal sealant
Microbial sealant (integuseal) applied with a sponge applicator

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • planned supragenual of infragenual peripheral arterial bypass procedures with autologue or prosthetic graft

Exclusion Criteria:

  • secondary procedures and suprainguinal procedures
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00940979

Contacts
Contact: Sjoerd A de Beer, MD 026378888 sdebeer@alysis.nl

Locations
Netherlands
Ziekenhuis Rijnstate Not yet recruiting
Arnhem, Netherlands, 6800 TA
Contact: Sjoerd A de Beer, MD     003126378888     sdebeer@alysis.nl    
Principal Investigator: Sjoerd A de Beer, MD            
Ziekenhuis Slingland Not yet recruiting
Doetinchem, Netherlands
Contact: Lemson, MD            
Principal Investigator: Lemson, MD            
Ziekenhuis Nij Smellinghe Not yet recruiting
Drachten, Netherlands
Contact: Wikkeling, MD            
Principal Investigator: Wikkeling, MD            
Sponsors and Collaborators
Rijnstate Hospital
Kimberly-Clark Corporation
Investigators
Study Director: Michel MPJ Reijnen, MD Rijstate hospital Arnhem the Netherlands
Study Director: J. Klinkenbijl, MD
Principal Investigator: Sjoerd A de Beer, MD Rijnstate Hospital Arnhem the Netherlands
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00940979     History of Changes
Other Study ID Numbers: LTC 625-230609
Study First Received: July 16, 2009
Last Updated: August 8, 2011
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Rijnstate Hospital:
Integuseal microbial sealant
Infection prophylaxis
Postoperative wound infection
Arterial bypass surgery

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 16, 2013